c-erbB-2 as a target for immunotherapy

Bibliography

• DOUGALL WC, QIAN X, PETERSON NC et al: The neu on-cogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene (1994) 9:2109–2123.
   PubMed Web of Science ®Google Scholar
• HYNES NE: Amplification and over-expression of theerbB-2 gene in human tumours: its involvement in tu-mour development, signficance as a prognostic factor and potential as a target for cancer therapy. Semin. Cancer Biol. (1993) 4:19–26.
   PubMed Web of Science ®Google Scholar
• GULLICK WJ: Type 1 growth factor receptors: currentstatus and future work. Biochem. Soc. Symp. (1998) 63:193–198.
   PubMedGoogle Scholar
• GRAUS-PORTA D, BEERLI RR, DALY JM, HYNES NE:ErbB-2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signalling. EMBO J (1997) 16: 1647-1655.
   Google Scholar
• BAST RC, BOYER CM, XU FJ: Selected molecular targetsfor diagnosis and therapy of epithelial ovarian cancer. Cancer Mol. Biol. (1994) 1:87–93.
   Google Scholar
• REVILLION F, BONNETERRE J, PEYRAT JP: erbB2 onco-gene in human breast cancer and its clinical signifi-cance. Eur. J. Cancer (1998) 34:791–808.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive recent review of 97 studies involving over22,000 patients. Careful consideration of the methodologies used and detailed analyses of all biological and clinical data render this an authoritative report.
   Google Scholar
• VAN DE VIVJER M, PETERSE JL, MOOT WJ et al.: Neu pro-tein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. New Eng. J. Med. (1988):1239–1245.
   Google Scholar
• MIZUTANI T, ONDA M, TOKUNAGE A, YAMANAKA N,SUGISAKI Y: Relationship of c-erbB-2 protein expres-sion and gene amplification to invasion and metasta-sis in human gastric cancer. Cancer (1993) 72:2083–2088.
   PubMed Web of Science ®Google Scholar
• SAKAMOTO H, DENG X, OHTANI K et al.: erbB-2, a c-erbB-2-coded protein, is expressed in metastatic cells of adenocarcinoma of endometrium, cervix and ovaries. Int. J. Gynecol. Cancer (1995) 5:11–415.
   Google Scholar
• NATALI PG, NICOTRA MR, BIGOTTI A et al.: Expression of the p185 encoded by HERZ oncogene in normal and transformed human tissues. Int. J. Cancer (1990) 45:457–461.
   PubMed Web of Science ®Google Scholar
• KERN JA, SCHWARTZ DA, NORDBERG JE et al.: p185' expression in human lung adenocarcinoma predicts shortened survival. Cancer Res. (1990) 50:5184–5191.
   PubMed Web of Science ®Google Scholar
• BERCHUCK A, KAMEL A, WHITAKER R et al.: Overexpres-sion of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. (1990) 50:4087–4091.
   PubMed Web of Science ®Google Scholar
• TATEISHI M, ISHIDA T, MITSUDOMI T, KANEKO S, SUGI-MACHI K: Prognostic value of c-erbB-2 protein expres-sion in human lung adenocarcinoma and squamous cell carcinoma. Eur. J. Cancer (1991) 27:1372–1375.
   PubMed Web of Science ®Google Scholar
• SHI D, HE G, CAO S et al.: Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Molec. Carcinogenesis (1992) 5:213–218.
   PubMed Web of Science ®Google Scholar
• PRESS MF, CORDON-CARDO C, SLAMON D: Expression of the HER-2/neu proto-oncogene in normal adult and fetal tissues. Oncogene (1990) 5:953–962.
   PubMed Web of Science ®Google Scholar
• GUY CT, WEBSTER MA, SCHALLER Metal.: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA (1992) 89:10578–10582.
   Google Scholar
• •First indication that in autochthonous hosts the neu gene is associated with metastatic disease.
   Google Scholar
• KATSUMATA M, OKUDAIRA T, SAMANTA A et al.: Preven-tion of breast tumour development in vivo by down-regulation of the p185neu receptor. Nature Med. (1995) 1:644–648.
   PubMed Web of Science ®Google Scholar
• PRESS MF, PIKE MC, CHAZIN VR et al.: Her-2/neu expres-sion in node-negative breast cancer: direct tissue quantitation by computerized analysis and association of over-expression with increased risk of recurrent disease. Cancer Res. (1993) 53:4960–4970.
   PubMed Web of Science ®Google Scholar
• •Direct clinical evidence that levels of p185 expression may be linked to tumour recurrence and metastasis.
   Google Scholar
• PANTEL K, SCHLIMOK G, BRAUN S et al.: Differential ex- pression of proliferation-associated molecules in indi-vidual micrometastatic carcinoma cells. J. Natl. Cancer Inst. (1993) 85:1419–1423.
   PubMed Web of Science ®Google Scholar
• •Interesting paper showing that disseminating micrometasta-ses often overexpress p185.
   Google Scholar
• TORP SH, HELSETH E, UNSGAARD G, DALEN A: C-erbB-2/HER-2 protein in human intracranial tu-mours. Eur. J. Cancer (1993) 29:1604–1606.
   Google Scholar
• BERNSTEIN JJ, ANAGNOSTOPOULOS AV, HATTWICK EA, LAWS ER: Human specific c-neu proto-oncogene over-expression in human malignant astrocytomas before and after xenografting. J. Neurosurg. (1993) 78:240–251.
   PubMed Web of Science ®Google Scholar
• JOHKI PP, KING A, LOKE YW: Reciprocal expression of epidermal growth factor receptor (EGF-ID and c-erbB2 by non-invasive and invasive human trophoblast populations. Cytokine (1994) 6:433–442.
   PubMed Web of Science ®Google Scholar
• YU D, WANG SS, DULSKI KM, TSAI C-M et al.: c-erbB-2/ neu over-expression enhances metastatic po-tential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. (1994) 54:3260–3266.
   PubMed Web of Science ®Google Scholar
• ••Direct evidence of the multiple mechanisms by whichc-erbB-2 may enhance metastasis in human tumour cells.
   Google Scholar
• WANG SW, YU D, HUNG MC, BOYD D: The proto-oncogene c-erbB2 (neu/Her-2) implicated in breast and lung cancer progression, upregulates urokinase plasminogen activator expression. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1994) 35:A439.
   Google Scholar
• BENZ CC, O'HAGAN RC, RICHTER B et al.: HER2/neu andthe Ets transcription factor PEA3 are coordinately upregulated in human breast cancer. Oncogene (1997) 15:1513–25.
   Google Scholar
• DE POTTER CR, QUATACKER J. The p185erbB2 protein islocalized on cell organelles involved in cell motility. Clin. Exp. Metastasis (1993) 11:453–461.
   PubMedGoogle Scholar
• CARRAWAY CAC, CARVAJAL ME, LI Y, CARRAWAY K: As-sociation of p185neu with microfilaments via a large glycoprotein complex in mammary carcinoma micro-villi . J. Biol. Chem. (1993) 268:5582–5587.
   PubMedGoogle Scholar
• SHIBATA T, OCHIAI A, KANAI Y et al.: Dominant nega-tive inhibition of the association between 8-catenin and c-erbB-2 by N-terminally deleted 8-catenin sup-presses the invasion and metastasis of cancer cells. Oncogene (1996) 13:883–889.
   PubMed Web of Science ®Google Scholar
• YU D, HAMADA JI, ZHAND H, NICOLSON GL, HUNG MC:Mechanisms of c-erbB-2/neu oncogene-induced me-tastasis and repression of metastatic properties by ad-enovirus 5 ElA gene products. Oncogene (1992) 7:2263–2270.
   PubMed Web of Science ®Google Scholar
• DE CORTE V, DE POTTER C, VANDENBURGHE D et al.: A50 kDa protein present in conditioned medium of COLO-16 cells stimulates cell spreading and motility, and activates tyrosine phosphorylation of neu/HER2, in SK-BR-3 mammary cancer cells. J. Cell Sci. (1994) 107:405–416.
   PubMed Web of Science ®Google Scholar
• PETIT AM, RAK J, HUNG M-C et al.: Neutralizing antibod-ies against epidermal growth factor and erbB-2 recep-tor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am. J. Pathol (1997) 151:1523–1531.
   PubMed Web of Science ®Google Scholar
• •Interesting paper showing that overexpression of EGFr or c-erbB-2 can induce vascular growth factor and, hence, may be involved in angiogenesis.
   Google Scholar
• ECCLES SA, MODJTAHEDI H, BOX G etal.: Significance of the c-erbB family of receptor tyrosine kinases in meta-static cancer and their potential as targets for immuno-therapy. Inv. Metast. (1995) 14:337–348.
   Google Scholar
• MARTH C, WIDSSCHWENDER M, KAERN J et al.: Cisplatin resistance is associated with reduced interferon gamma sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. Br. J. Cancer (1997) 76:1328–1332.
   PubMed Web of Science ®Google Scholar
• GUSTERSON BA, GELBER RD, GOLDHIRSCH A et al.: Prog-nostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol. (1992) 10:1049–1056.
   PubMed Web of Science ®Google Scholar
• TSAI C-M, CHANG K-T, PERNG R-P et al.: Correlation ofintrinsic chemoresistance of non-small cell lung can-cer cell lines with HER-2/neu gene expression but not with ras gene mutations. J. Natl. Cancer Inst. (1993) 85:897–901.
   PubMed Web of Science ®Google Scholar
• CARLOMAGNO C, PERRONE F, GALLO C et al.: c-erbB-2 overexpression decreases the benefit of adjuvant ta-moxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol. (1996) 14:2702–2708.
   PubMed Web of Science ®Google Scholar
• BIANCO AR, DE LAURENTIS M, CARLOMAGNO C et al.: 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-B2 expression and tamoxifen efficacy. Proc. Am. Soc. Clin. Oncol. (1998) 17:97a. Abstract 373.
   Google Scholar
• ••Long follow-up, large scale trial showing unequivocal evi-dence of interactions between c-erbB-2 and Tamoxifen sen-sitivity in subsets of patients.
   Google Scholar
• LICHTENSTEIN A, BERENSON J, GERA JF et al: Resistance of human ovarian carcinoma cells to tumor necrosis factor and lymphokine activated killer cells: correla-tion with expression of HER2/neu oncogenes. Cancer Res. (1990) 50:7364–7370.
   PubMed Web of Science ®Google Scholar
• TORRE EA, SALIMBENI V, FULCO RA: The erbB2 onco-gene and chemotherapy: a minireview. J. Chem other. (1997) 9:51–55.
   Google Scholar
• WRIGHT C, NICHOLSON S, ANGUS B et al.: Relationship between c-erbB2 protein product expression and re-sponse to endocrine therapy in advanced breast can-cer. Br. J. Cancer (1992) 65:118–121.
   PubMed Web of Science ®Google Scholar
• BORG A, TANDON AK, SIGURDSSON H et al.: Her-2/neu amplification predicts poor survival in node positive breast cancer. Cancer Res. (1990) 50:4332–4337.
   PubMed Web of Science ®Google Scholar
• ELLEDGE RM, GREEN S, CIOCCA D et al.: HER-2 expres-sion and response to Tamoxifen in estrogen recptor-positive breast cancer: a Southwest Oncology Group study. Clin. Cancer Res. (1998) 4:7–12.
   PubMed Web of Science ®Google Scholar
• MUSS HB, THOR AD, BERRY DA et al.: c-erbB-2 expres-sion and response to adjuvant therapy in women with node-positive early breast cancer. New Eng. J. Med. (1994) 330:1260–1266.
   PubMed Web of Science ®Google Scholar
• BASELGA J, SEIDMAN AD, ROSEN PP, NORTON L: HERZoverexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (1997) 11:43–48.
   PubMedGoogle Scholar
• PEGRAM MD, FINN RS, ARZOO K et al.: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene (1997) 15:537–547.
   PubMed Web of Science ®Google Scholar
• MENDELSOHN J, FAN Z: Epidermal growth factor recep-tor family and chemosensitization. J. Natl. Cancer Inst. (1997) 89:341–343.
   PubMed Web of Science ®Google Scholar
• ARTEAGA CL, WINNIER AR, POIRIER MC et al.: p185c-erb13-2 signalling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. (1994) 54:3758–3665.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI H, O'NEILL A, GELMAN R et al: Prediction ofresponse to anti-estrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/neu protein. J. Clin. Oncol. (1997) 15:2518–2525.
   PubMed Web of Science ®Google Scholar
• TANG RP, KACINSKI B, VALIDIRE P et al.: Oncogene am-plification correlates with dense lymphocytic infiltra-tion in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J. Cell. Biochem. (1990) 44:189–198.
   PubMedGoogle Scholar
• DISIS ML, CHEEVER MA, et al.: HER-2/neu protein: a tar-get for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. (1997) 17:343–371.
   Google Scholar
• BEI R, MASUELLI L, MORICONI E et al.: Simultaneous im- mune response to multiple erbB receptors detectable in serum of cancer patients. Proc. Am. Assoc. Cancer Res. (1998) 39:65.
   Google Scholar
• •Evidence that patients recognise 'self c-erbB protein prod-ucts and the predominance of c-erbB-2 responses.
   Google Scholar
• NAGATA Y, FURUGEN R, HIASA A et al.: Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor sup-pression in syngeneic hosts. J. Immunol. (1997) 159:1336–1343.
   PubMed Web of Science ®Google Scholar
• PEOPLES GE, GOEDEGEBURRE PS, SMITH R et al.: Breastand ovarian cancer-specific cytotoxic T lymphocytes recognise the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA (1995) 92:432–436.
   PubMed Web of Science ®Google Scholar
• FISK B, LEVINS TL, WHARTON JT, IOANNIDES CG: Identi-fication of an immunodominant peptide of HER-2/en protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. (1995) 181:2109–2117.
   PubMed Web of Science ®Google Scholar
• YOSHINO I, GOEDEGBUURE PS, PEOPLES G et al.:HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res. (1994) 54:3387–3390.
   PubMed Web of Science ®Google Scholar
• PEIPER M, GOEDEGBUURE PS, LINEHAM DC et al: TheHER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recog-nized by cytotoxic T lymphocytes. Eur. J. Immunol (1997) 27:1115–1123.
   PubMed Web of Science ®Google Scholar
• BROSSART P, STUHLER G, FLAD T et al.: Her-2/neu-d-erived peptides are tumor-associated antigens ex-pressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. (1998) 58:732–736.
   PubMed Web of Science ®Google Scholar
• IOANNIDES CG, FISK B, FAN D et al.: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER2/neu proto-oncogene. Immunol. (1993) 151:225–230.
   Web of Science ®Google Scholar
• FISK B, HUDSON JM, KAVANAGH J, etal.: Existent prolif-erative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res. (1997) 17:45–54.
   Google Scholar
• GOEDEGEBUURE PS, DOUVILLE CC, DOHERTY JM et al.: Simultaneous production of T-helper-l-like cytokines and cytolytic activity by tumor-specific T cells in ovar-ian and breast cancer. Cell. Immunol. (1997) 175:150–156.
   PubMed Web of Science ®Google Scholar
• LINEHAN DC, GOEDEGEBURRE PS, PEOPLES GE, ROGERSSO, EBERLEIN TJ: Tumor-specific and HLA-restricted cy-tolysis by tumor-associated lymphocytes in human © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(11) metastatic breast cancer. J. Immunol, (1995) 155:4486–4491.
   Google Scholar
• DISIS ML, GRALOW JR, BERNHARD H eta].: Peptide-based but not whole protein vaccines elicit immunity to HER-2/neu oncogenic self protein. J. Immunol. (1996) 156:3151–3158.
   Google Scholar
• •Illustrates the importance of peptide vaccines to overcome self-tolerance.
   Google Scholar
• PARDOLL DM: Cancer vaccines. Nature Med. (1998)4:525–531.
   PubMed Web of Science ®Google Scholar
• DISIS ML, GRABSTEIN KH, SLEATH PR, CHEEVER MA:(HER-2/neu peptide vaccines elicit T cell immunity to the HER-2/neu protein in patients with breast and ovarian cancer. Proc. Am. Soc. Clin. Oncol. (1998) 17:97a. Abstract 375.
   Google Scholar
• ROMANI N, REIDER D, HEUER M et al: Generation of ma-ture dendritic cells from human blood; an improved method with special regard to clinical applicability. J. Immunol. Methods (1996) 196:137–151.
   PubMed Web of Science ®Google Scholar
• KLAPPER LN, VAISMAN N, HURWITZ E et al: A subclass of tumor-inhibitory monoclonal antibodies to erbB2/HER2 blocks crosstalk with growth factor re-ceptors. Oncogene (1997) 14:2099–2109.
   PubMed Web of Science ®Google Scholar
• •Key paper showing that a wide range of mAbs against c-erbB-2 can be generated with markedly different proper-ties, and the potential of some of them to inhibit signalling induced by ligands for other c-erbB family members.
   Google Scholar
• DEAN CJ, ALLAN S, ECCLES S et al.: The product of the c-erbB-2 proto-oncogene as a target for diagnosis and therapy in breast cancer. Year Immunol. (1993) 7:182–192.
   PubMedGoogle Scholar
• O'ROURKE DM, GREENE MI: Immunologic approaches to inhibiting cell-surface residing oncoproteins in hu-man tumors. Immunol. Res. (1998) 17:179–189.
   PubMed Web of Science ®Google Scholar
• KITA Y, TSENG J, HORAN T et al.: erbB receptor activa-tion, cell morphology changes and apoptosis induced by anti-HER2 monoclonal antibodies. Biochem. Bio-phys. Res. Commun. (1996) 226:59–69.
   PubMed Web of Science ®Google Scholar
• COBLEIGH MA, VOGEL CL, TRIPATHY D et al.: Efficacy and safety of Herceptin (humanized anti-HER2 anti-body) as a single agent in 222 women with HERZ over-expression who relapsed following chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (1998) 17:97a Abstract 376.
   Google Scholar
• ••Important study showing the potential of anti-c-erbB-2 mAbalone to produce responses in some late-stage cancer patients.
   Google Scholar
• HEIJNEN IAFM, RIJKS LJM, SCHIEL A et al.: Generation ofHER-2/neu specific cytotoxic neutrophils in viva effi-cient arming of neutrophils by combined administra-tion of granulocyte colony stimulating factor and Fcy receptor 1 specific antibodies. J. Immunol. (1997) 159:5629–5639.
   PubMed Web of Science ®Google Scholar
• VALONNE FH, KAUFMAN PA, GUYRE P et al.: Phase Ia/Ibtrial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol. (1995) 13:2281–2292.
   PubMed Web of Science ®Google Scholar
• VAN OJIK HH, REPP R, GROENEWEGEN G, eta].: Phase I trial of bispecific antibody MDX-11210 (FcyR1 x HER-2/neu) in combination with G-CSF in patients with stage IV metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (1998) 17:448a. Abstract 1728.
   Google Scholar
• JAMES N, ATHERTON P, KOLETSKY A, TCHEKMEDYIAN N, CURNOW R: Phase II trial of the bispecific antibody MDX-11210 (anti-HER2/neu x anti-CD64) combined with GM-CSF in patients with advanced prostate and renal cell carcinomas that express HER2/neu. Proc. Am. Soc. Clin. Oncol (1998) 17:436a. Abstract 1681.
   Google Scholar
• •One of the first studies to show objective clinical responses of a bispecific (p185 x FcyR1) mAb in late stage cancer patients.
   Google Scholar
• WEINER LM, CLARK JI, DAVEY M et al.: Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. (1995) 55:4586–4593.
   PubMed Web of Science ®Google Scholar
• CLARK JI, ALPAUGH RK, VON MEHREN Metal.: Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol Im-munother. (1997) 44:265–272.
   Google Scholar
• SHALABY MR, CARTER P, MANEVAL D, GILTINAN D, KOTTS C: Bispecific HERZ x CD3 antibodies enhance cytotoxicity in vitro and localize to HERZ-overexpressing xenografts in nude mice. Clin. Immu-nol Immunopathol (1995) 74:185–192.
   PubMedGoogle Scholar
• ZHU Z, LEWIS G, CARTER P: Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(abl2 for efficient lysis of p185HER2 overexpressing tumor cells. Int. J. Cancer (1995) 62:319–324.
   PubMed Web of Science ®Google Scholar
• DI LAZZARO C, DIGIESI G, TECCE R et al: Immunotoxins to the HER-2 oncogene product: functional and ultra-structural analysis of their cytotoxic activity. Cancer Immunol. Immunother. (1994) 39:318–324.
   PubMed Web of Science ®Google Scholar
• PARK JW, HONG K, CARTER P et al.: Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA (1995) 92:1327–1331.
   PubMed Web of Science ®Google Scholar
• GOREN D, HOROWITZ AT, ZALIPSKY S etal.: Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer (1996) 74:1749–1756.
   Google Scholar
• ECCLES SA, COURT WJ, BOX GA eta].: Regression of es-tablished breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB-2 p185. Cancer Res. (1994) 54:5171–5177.
   Google Scholar
• •Paper showing the potential of high affinity, non-internalising anti-c-erbB-2 mAbs for 2-stage targeted therapies.
   Google Scholar
• FRITZBERG AR: Antibody pretargeted radiotherapy: a new approach and a second chance. J. Nucl. Med. (1998) 39:20N–36N.
   Google Scholar
• PIETRAS RJ, FENDLY BM, CHAZIN VR eta].: Antibody toHER2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 9:1829–1838.
   Google Scholar
• HANCOCK MC, LANGTON BC, CHAN T et al A mono- clonal antibody against the c-erbB-2 protein enhances © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(11) the cytotoxicity of cis-diaminodichloroplatinum against human breast and ovarian carcinoma cell lines. Cancer Res. (1991) 4575–4580
   Google Scholar
• SLAMON D, LEYLAND-JONES B, SHAK S et al: Addition ofHerceptin (humanized anti-HER2 antibody) to first line chemotherapy for HERZ overexpressing meta-static breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized multinational con-trolled Phase III trial. Proc. Am. Soc. Clin. Oncol (1998) 17:98a. Abstract 377.
   Google Scholar
• CLARK MA, HAWKINS NJ, PAPAIOANNOU A, FIDDES RJ,WARD RL: Isolation of human anti-c-erbB Fabs from a lymph node-derived phage display library. Clin. Exp. Immunol. (1997) 109:166–174.
   PubMed Web of Science ®Google Scholar
• SCHIER R, MCCALL A, ADAMS GP: Isolation of picomolaraffinity anti-c-erbB-2 single chain fv by molecular evo-lution of the complementarity determining regions in the center of the antibody combining site. J. Mol. (1996) 263:551–567.
   PubMed Web of Science ®Google Scholar
• ISAACS JD, WALDMANN H: Helplessness as a strategyfor avoiding antiglobulin responses to therapeutic monoclonal antibodies. Ther. Immunol (1994) 1:303–312.
   PubMedGoogle Scholar
• ADAMS GP, SCHIER R, McCALL AM et al: Prolonged invivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer (1998) 77:1405–1412.
   PubMed Web of Science ®Google Scholar
• WELS W, GRONER B, HYNES NE: Intervention in recep-tor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to erbB2. Curr. Top. Microbiol. Immunol. (1996) 213:113–128.
   PubMed Web of Science ®Google Scholar
• •Good review of the scfv approach.
   Google Scholar
• DESHANE J, SIEGAL GP, ALVAREZ RD et al.: Targeted tu-mor killing via an intracellular antibody against erbB-2. j Clin. Invest. (1995) 96:2980–2989.
   PubMed Web of Science ®Google Scholar
• VENANZI FM, PETRELLI C, CONCETTI A, AMICI C:neu/HER-2 cDNA vaccination and pregnancy loss. Ann. NY Acad. Sci. (1995) 772:274–277.
   PubMed Web of Science ®Google Scholar
• MARTH C, CRONAUER MV, DOPPLER W et al.: Effects ofinterferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. Int. J. Cancer (1992) 50:64–68.
   PubMed Web of Science ®Google Scholar
• KONO K, HISING C, PETERSON M et al.: Mechanisms ofescape from CD8+ T-cell clones specific for the HER-2/ENproto-oncogene expressed in ovarian carci-nomas: related and unrelated to decreased MHC class 1 expression. Int. J. Cancer (1997) 70:112–119.
   PubMed Web of Science ®Google Scholar
• GERSTMEYER B, ALTENSCHMIDT U, HOFFMANN M, WELSW: Costimulation of T cell proliferation by a chimeric B7.2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. J. Immunol. (1997) 158:4584–4590.
   Google Scholar
• WILTSCHKE C, TYL E, STEININGER A et al: Increased NKcell activity correlates with low or negative expression of the HER-2/neu oncogene in breast cancer patients. Proc. Am. Assoc. Cancer Res. (1991) 32:203.
   Google Scholar
• QUERZOLI P, MARCHETTI E, FABRIS G etal: Immunohis-tochemical expression of c-erbB-2 in human breast cancer by monoclonal antibody: correlation with lymph node and ER status. Tumor' (1990) 76:461–464.
   PubMed Web of Science ®Google Scholar
• KALLIONIEMI OP, HOLLI K, VISAKORPI T et al.: Associa-tion of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral me-tastasis and poor long term survival in breast cancer. Int. J. Cancer (1991) 49:650–655.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707–712.
   PubMed Web of Science ®Google Scholar
• SIMPSON BJB, PHILLIPS HA, LESSELLS AM, LANGDON SP, MILLER WR: c-erbB growth factor-receptor proteins in ovarian tumours. Int. J. Cancer (1995) 64:202–206.
   PubMed Web of Science ®Google Scholar
• MITRA AB, MURTY VVVS, PRATAP M, SODHANI P, CHA-GANTI RSK: erbB2 (HER2/neu oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res. (1994) 54:637–639.
   PubMed Web of Science ®Google Scholar
• OKA K, NAKANO T, ARAI T: c-erbB oncoprotein expres-sion is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer (1994):668–671.
   Web of Science ®Google Scholar
• NEIHANS GA, SINGLETON TP, DYKOSKI D, KIANG DT: Stability of HER-2/neu expression over time and at multiple metastatic sites. J. Natl. Cancer Inst. (1993) 85:1230–1235.
   PubMed Web of Science ®Google Scholar
• LIPPONEN PK: Interrelationship between expression of p53, proliferating cell nuclear antigen and c-erbB-2 in bladder cancer. Pathobiology (1993) 61:178–182.
   PubMed Web of Science ®Google Scholar
• WRIGHT C, MELLON K, JOHNSON P et al: Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br. J. Cancer (1991) 63:967–970.
   PubMed Web of Science ®Google Scholar
• MORIYAMA M, AKIYAMA T, YAMAMOTO T et al: Expres-sion of c-erbB-2 gene product in urinary bladder can-cer. J. Urol. (1991) 145:423–427.
   PubMed Web of Science ®Google Scholar
• STUMM G, EBERWEIN S, ROSTOCK-WOLF S et al.: Con-comitant over-expression of the EGFR and c-erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int. J. Cancer (1996) 69:17–22.
   PubMed Web of Science ®Google Scholar
• ROYCHOWDHURY D, TSENG A, FU K, WEINBERG V, WEIDNER N: New prognostic factors in nasopharyn-geal carcinoma. Cancer (1996) 77:1419–1426.
   PubMed Web of Science ®Google Scholar
• HARPOLE DH, HERNDON JE, WOLFE WG, INGLEHARD JD, MARKS JR: A prognostic model of recurrence and death in stage 1 non-small cell lung cancer utilizing presentation, histopathology and oncoprotein ex-pression. Cancer Res. (1995) 55:51–56.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, NEKARDA H, HOELSCHER AH: Prognostic value of DNA ploidy and c-erbB-2 oncoprotein expres-sion in adenocarcinoma of the Barrett's oesophagus. Cancer (1994) 73: 1785-1794.
   Google Scholar
• TSUJINO T, YOSHIDA K, NAKAYAMA H et al.: Alterations of oncogenes in metastatic tumours of human gastric carcinomas. Br. J. Cancer (1990) 62:226–230.
   PubMed Web of Science ®Google Scholar
• LEE EY, CIBULL ML, STRODEL WE, HALEY JV: Expression of HER-2/neu overexpression and epidermal growth factor and prognosis in gastric carcinoma. Arch. Pa-thol. Lab. Med. (1994) 118:235–239.
   PubMed Web of Science ®Google Scholar
• WANG SQ, WU RH, ZHUANG WC: Significance of the ex-pression of c-erbB-2 oncoprotein, human epidermal growth factor and its receptor in human colon cancer. Chin. J. Clin. Oncol (1995) 22:315–318.
   Google Scholar
• SHWECHEIMER K, LAUFLE RM, SCHMAL W et al.: Expres-sion of neu/c-erbB-2 in human brain tumors. Hum. Pa-thol. (1994) 25:772–780.
   PubMed Web of Science ®Google Scholar
• HIESEGER EM, HAYES RL, BUDZILOVICH GN, PIERZ DM, RANSOHOFF J: erbB2 (HER2/neu) and epidermal growth factor (EGFR) expression are prognostic fac-tors in glioblastoma (GBM). Proc. Ann. Meet. Am. Assoc. Cancer Res. (1992) 33:A1522.
   Google Scholar
• YAMANAKA Y, FREISS H, KOBRIN MS et al.: Overexpres-sion of HER2/neu oncogene in human pancreatic car-cinoma. Hum. Pathol (1993) 24:1127–1134.
   PubMed Web of Science ®Google Scholar
• NATALI PG, NICOTRA MR, DIGIESI G et al: Expression of gp 185 HER-2 in human cutaneous melanoma: implica-tions for experimental immunotherapeutics. Int. J. Cancer (1994) 56:341–346.
   PubMed Web of Science ®Google Scholar
• DISIS ML, CALENOFF E, MCLAUGHLIN G et al.: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. (1994) 54:16–20.
   PubMed Web of Science ®Google Scholar
• SHEPARD HM, LEWIS GD, SARUP JC et al.: Monoclonal antibody therapy of human cancer: taking the HERZ protooncogene to the clinic. J. Clin. Immunol. (1991) 11:117–127.
   PubMed Web of Science ®Google Scholar
• BATRA JK, KASPRZYK PG, BIRD RE, PASTAN I, RICHTER KING C: Recombinant anti-erbB2 immunotoxins con-taining Pseudomonas exotoxin. Proc. Natl. Acad. Sci. (1992) 89:5867–5871.
   PubMed Web of Science ®Google Scholar
• SMELLIE WJB, DEAN CJ, SACKS NPM et al.: Radioimmuno-therapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-buty-lstannyl) benzoate radioiodination methods. Cancer Res. (1996) 55:5842–5846.
   Google Scholar
• DE SANTES K, SLAMON D, ANDERSON SK et al.: Radiola-beled antibody targeting of the HER-2/neu oncopro-tein. Cancer Res. (1992) 52:1916–1923.
   PubMed Web of Science ®Google Scholar
• PARK JW, KIRPOTIN D, SHALABY R et al.: Anti-HER2 im-munoliposomes: significantly superior efficacy vs. Doxorubicin, liposomal doxorubicin, and anti-HER2 antibody treatment via a novel mechanism of action. Proc. Am. Soc. Clin. Oncol. (1998) 17:216a. Abstract 833.
   Google Scholar
• WEINER LM, HOLMES M, ADAMS GP et al.: A human tu-mour xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res. (1993) 53:94–100.
   PubMed Web of Science ®Google Scholar
• MORITZ D, WELS W, MATTERN J, GRONER B: Cytotoxic T lymphocytes with a grafted recognition specificity for erbB2-expressing tumor cells. Proc. Natl. Acad. Sci. USA (1994) 91:4318–4322.
   PubMed Web of Science ®Google Scholar
• WATANABE T, TOKUDA Y, SASAKI Y, ADACHI I, TAJIMA T: Pharmacokinetically guided dose escalation study of anti-HER2 monoclonal antibody in patients with Her2/neu-overexpressing metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (1998) 17:182a. Abstract 702.
   Google Scholar
• BASELGA J, TRIPATHY D, MENDELSOHN J et al.: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-over-expressing metastatic breast cancer. J. Clin. Oncol. (1996) 14:737–744.
   PubMed Web of Science ®Google Scholar
• PEGRAM M, LIPTON A, PIETRAS R et al.: Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer. Proc. Am. Assoc. Clin. Oncol. (1995) 14.Ab-stract 124.
   Google Scholar
• DISIS ML, CHEEVER MA. HER-2/neu oncogenic protein: issues in vaccine development. Grit. Rev. Immunol. (1998) 18:37–45.
   PubMed Web of Science ®Google Scholar
• ••Excellent recent review clearly outlining design imperativesfor effective 'self antigen vaccines.
   Google Scholar